Literature DB >> 16945492

Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release.

C Martínez-Sancho1, R Herrero-Vanrell, S Negro.   

Abstract

The aim of this study was to obtain a prolonged release of Vitamin A palmitate (RAP) and aciclovir from biodegradable microspheres for intraocular administration with an antiviral action and to be capable of preventing the inherent risks of intravitreal administration. The RAP effect on the microsphere characteristics was also studied. Poly(D,L-lactic-co-glycolic) acid microspheres were prepared by the solvent evaporation method. Different quantities of aciclovir (40-80 mg) and RAP (10-80 mg) were added to the internal phase of the emulsion. Microspheres were analysed by scanning electron microscopy, which revealed a spherical surface and a porous structure, and granulometric analysis that showed an adequate particle size for intraocular administration. The aciclovir loading efficiency increased when Vitamin A palmitate was added. Differential scanning calorimetry detected no differences in the polymer glass transition temperature and the aciclovir melting endotherm in all formulations. The release of aciclovir during the first days of the in vitro assay was improved with respect to microspheres without RAP. The microspheres showed a constant release of aciclovir and RAP for 49 days. Best results were obtained for microspheres prepared with 40 mg aciclovir, 80 mg RAP and 400mg polymer. A dose of 4.74 mg of microspheres would be therapeutic for the herpes simplex and Epstein-Barr viruses' treatment in an animal model and would reduce the intravitreal adverse effects. The injectability of a suspension of microspheres in isotonic saline solution resulted appropriate for its injection through a 27 G needle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945492     DOI: 10.1016/j.ijpharm.2006.07.010

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

Review 1.  Drug and gene delivery to the back of the eye: from bench to bedside.

Authors:  Cheryl L Rowe-Rendleman; Shelley A Durazo; Uday B Kompella; Kay D Rittenhouse; Adriana Di Polo; Alan L Weiner; Hans E Grossniklaus; Muna I Naash; Alfred S Lewin; Alan Horsager; Henry F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-28       Impact factor: 4.799

2.  Drug delivery to the posterior segment of the eye for pharmacologic therapy.

Authors:  Shalin S Shah; Lori Vidal Denham; Jasmine R Elison; Partha S Bhattacharjee; Christian Clement; Tashfin Huq; James M Hill
Journal:  Expert Rev Ophthalmol       Date:  2010-02-01

3.  Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time.

Authors:  Amany O Kamel; Gehanne A S Awad; Ahmed S Geneidi; Nahed D Mortada
Journal:  AAPS PharmSciTech       Date:  2009-12-01       Impact factor: 3.246

4.  Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits.

Authors:  Zhuo Ye; Yan-Li Ji; Xiang Ma; Jian-Guo Wen; Wei Wei; Shu-Man Huang
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

5.  Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits.

Authors:  Linhua Zhang; Yue Li; Chao Zhang; Yusheng Wang; Cunxian Song
Journal:  Int J Nanomedicine       Date:  2009-09-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.